Abstract:Supplementary Figure S1 shows synthesis and characterization of PLSWT7-DMI. (A) Visible absorption spectrum of PLSWT7-DMI. Similar absorption peaks were observed for PLSWT7-DMI and IRDye800CW (~774 nm). (B) Absorbance stability of PLSWT7-DMI. The absorbance dropped to <10% within 48 h. (C) CCK8 assay of the effects of various concentrations of PLSWT7-DMI on RT112 and EJ cell viability at 24 or 48 h. There were no significant differences in cytotoxicity for all concentrations among groups (p > 0.05). (D) Fluorescence intensity of RT112 and EJ cells incubated with various concentrations of PLSWT7-DMI. Cells incubated with 180 pmol/mL PLSWT7-DMI produced the highest fluorescence. Supplementary Figure S2 shows fluorescence microscopy images of SV-HUC-1 cells incubated with PLSWT7-DMI. Minimal fluorescence was observed after incubation. Supplementary Figure S3 shows metabolic profiles of PLSWT7-DMI post-intravenous-injection via the tail vein. (A) IVIS imaging of subcutaneous tumor-bearing mice injected with cPLSWT7-DMI and PLSWT7-DMI. Red circle indicates the tumor region. (B) Fluorescence intensity of the tumor site in (A). PLSWT7-DMI-treated groups exhibited higher fluorescence intensity than that of cPLSWT7-DMI-treated groups. (C) Comparison of TBR profiles of PLSWT7-DMI and cPLSWT7-DMI. TBR of PLSWT7-DMI-treated groups peaked 8 h post-injection and was higher than the TBR of control groups. Values are presented as means {plus minus} SD of 5 animals. Supplementary Figure S4 shows ex vivo imaging of mouse organs at 6-h post-instillation of PLSWT7-DMI. (A) A bright signal was observed in RT112 tumors, whereas signals in organs were minimal. (B) Quantitative analysis of the fluorescence intensity observed in (A). Values are presented as means {plus minus} SD of 5 animals. Supplementary Figure S5 shows orthotopic BC mice imaging. (A) Luciferase imaging showing tumor growth in the orthotopic BC model. (B) NIR imaging of orthotopic BC mice post-instillation of the probes. Bladders of orthotopic BC mice instilled with PBS, cPLSWT7-DMI, PLSWT7-DMI with blockade, or PLSWT7-DMII, followed by imaging using a homemade NIR-imaging system at 30-min post-instillation. Tumors in PLSWT7-DMI groups were clearly visualized; however, the blockade of PLSWT7-DMI binding to the tumor was observed following PLSWT7 pretreatment. The yellow-dashed circle indicates the tumor site. (C) Quantitative analysis of the mean fluorescence density shown in (B). Values are presented as means {plus minus} SD of 5 animals. *p < 0.05 vs. PLSWT7-DMI+blockade groups. Supplementary Figure S6 shows PAI of subcutaneous tumor-bearing mice after intravenous injection via the tail vein. (A) PAI of subcutaneous tumor-bearing mice. Subcutaneous tumor-bearing mice were injected with PBS, cPLSWT7-DMI, PLSWT7-DMI with blockade, or PLSWT7-DMI via tail vein, followed by PAI. PLSWT7-DMI-treated groups exhibited enhanced contrast compared with other groups. The red-dashed circle indicates the tumor site. (B) Quantification of the average PA-signal amplitude of subcutaneous tumor-bearing mice in (A). The PLSWT7-DMI groups exhibited higher signals than those of other groups. Values present means {plus minus} SD of 5 animals. *p < 0.05 vs. PLSWT7-DMI + blockade groups. Supplementary Figure S7 shows ex vivo human bladder imaging post-administration of cPLSWT7-DMI. No optical contrast between cancer and normal tissues was observed post-administration of cPLSWT7-DMI.

Renal-clearable Macromolecular Reporter for Near-infrared Fluorescence Imaging of Bladder Cancer.

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Developing A Bright Nir-Ii Fluorophore With Fast Renal Excretion And Its Application In Molecular Imaging Of Immune Checkpoint Pd-L1

A Renal-Clearable Activatable Molecular Probe for Fluoro-Photacoustic and Radioactive Imaging of Cancer Biomarkers

Glycosylated Phospholipid-Coated Upconversion Nanoparticles for Bioimaging of Non-Muscle Invasive Bladder Cancers

A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer

In Vivo Optical Imaging of Bladder Cancer Tissues in an MB49 Bladder Cancer Orthotopic Mouse Model Using the Intravesical or Intravenous Administration of Near-Infrared Fluorescence Probe

Surface-Enhanced Raman Scattering Nanoparticles for Multiplexed Imaging of Bladder Cancer Tissue Permeability and Molecular Phenotype

Renal-clearable Nanoprobes for Optical Imaging and Early Diagnosis of Diseases

Ex vivo near-infrared targeted imaging of human bladder carcinoma by ICG-anti-CD47

Molecular Cancer Imaging in the Second Near‐Infrared Window Using a Renal‐Excreted NIR‐II Fluorophore‐Peptide Probe

A Near-Infrared Peptide Probe with Tumor-Specific Excretion-Retarded Effect for Image-Guided Surgery of Renal Cell Carcinoma.

Multiplex Ratiometric Gold Nanoprobes Based on Surface-Enhanced Raman Scattering Enable Accurate Molecular Detection and Imaging of Bladder Cancer

A novel bidirectional perfusion-like administered system for NIR-II fluorescence imaging precision diagnosis of bladder cancer

Supplementary Figures S1-S7 from Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study

A Bright, Renal‐Clearable NIR‐II Brush Macromolecular Probe with Long Blood Circulation Time for Kidney Disease Bioimaging

Novel Application of Cell Penetrating R11 Peptide for Diagnosis of Bladder Cancer

In Situ imaging of orthotopic kidney cancer in the murine model using an aminopeptidase N activatable fluorescent probe

Fluoro‐Photoacoustic Polymeric Renal Reporter for Real‐Time Dual Imaging of Acute Kidney Injury

Renal Clearable Magnetic Nanoreporter for Colorimetric Urinalysis of Tumor

Targeted delivery of nuclear targeting probe for bladder cancer using cyclic pentapeptide c(RGDfK) and acridine orange